JP2013505249A - Ｂｃｌ−２タンパク質関連疾患の治療における使用のためのＡＢＴ−２６３結晶形態および溶媒和物 - Google Patents

Ｂｃｌ−２タンパク質関連疾患の治療における使用のためのＡＢＴ−２６３結晶形態および溶媒和物 Download PDF

Info

Publication number
JP2013505249A
JP2013505249A JP2012529878A JP2012529878A JP2013505249A JP 2013505249 A JP2013505249 A JP 2013505249A JP 2012529878 A JP2012529878 A JP 2012529878A JP 2012529878 A JP2012529878 A JP 2012529878A JP 2013505249 A JP2013505249 A JP 2013505249A
Authority
JP
Japan
Prior art keywords
cancer
abt
free base
crystalline
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012529878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505249A5 (enExample
Inventor
ジヤン，ジエフ・ジー・ゼツト
ブレツケマイヤー，ポール・ジエイ
カトロン，ナサニエル・デイー
ボーチヤート，トーマス・ビー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2013505249A publication Critical patent/JP2013505249A/ja
Publication of JP2013505249A5 publication Critical patent/JP2013505249A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012529878A 2009-09-20 2010-09-15 Ｂｃｌ−２タンパク質関連疾患の治療における使用のためのＡＢＴ−２６３結晶形態および溶媒和物 Pending JP2013505249A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24405109P 2009-09-20 2009-09-20
US61/244,051 2009-09-20
PCT/US2010/048949 WO2011034934A1 (en) 2009-09-20 2010-09-15 Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015142670A Division JP2015232006A (ja) 2009-09-20 2015-07-17 Ｂｃｌ−２タンパク質関連疾患の治療における使用のためのＡＢＴ−２６３結晶形態および溶媒和物

Publications (2)

Publication Number Publication Date
JP2013505249A true JP2013505249A (ja) 2013-02-14
JP2013505249A5 JP2013505249A5 (enExample) 2013-10-31

Family

ID=43064468

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012529878A Pending JP2013505249A (ja) 2009-09-20 2010-09-15 Ｂｃｌ−２タンパク質関連疾患の治療における使用のためのＡＢＴ−２６３結晶形態および溶媒和物
JP2015142670A Pending JP2015232006A (ja) 2009-09-20 2015-07-17 Ｂｃｌ−２タンパク質関連疾患の治療における使用のためのＡＢＴ−２６３結晶形態および溶媒和物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015142670A Pending JP2015232006A (ja) 2009-09-20 2015-07-17 Ｂｃｌ−２タンパク質関連疾患の治療における使用のためのＡＢＴ−２６３結晶形態および溶媒和物

Country Status (15)

Country Link
US (2) US8362014B2 (enExample)
EP (1) EP2477972A1 (enExample)
JP (2) JP2013505249A (enExample)
KR (1) KR20120085781A (enExample)
CN (2) CN105820138A (enExample)
AU (1) AU2010295717B2 (enExample)
BR (1) BR112012006252A2 (enExample)
CA (1) CA2771984A1 (enExample)
IL (1) IL218403A0 (enExample)
MX (1) MX2012003408A (enExample)
NZ (1) NZ598461A (enExample)
RU (1) RU2551376C2 (enExample)
TW (1) TWI488853B (enExample)
WO (1) WO2011034934A1 (enExample)
ZA (1) ZA201202891B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014162794A (ja) * 2013-02-21 2014-09-08 Pfizer Inc 選択的ｃｄｋ４／６阻害剤の固体形態

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102209729B (zh) * 2008-11-07 2016-05-25 安进研发（慕尼黑）股份有限公司 小儿急性淋巴细胞白血病的治疗方法
RS58827B1 (sr) 2008-11-07 2019-07-31 Amgen Res Munich Gmbh Tretiranje akutne limfoblastne leukemije
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) * 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
CN105820138A (zh) 2009-09-20 2016-08-03 Abbvie 公司 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物
JP5779591B2 (ja) * 2009-12-22 2015-09-16 アッヴィ・インコーポレイテッド Ａｂｔ−２６３カプセル剤
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2014160071A1 (en) 2013-03-14 2014-10-02 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
CA2909380A1 (en) * 2013-04-21 2014-10-30 Yeda Research And Development Co. Ltd. Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
EP3099380B1 (en) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
WO2015157120A1 (en) * 2014-04-06 2015-10-15 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
CN108727387B (zh) * 2018-07-25 2021-03-16 天津大学 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法
CN109053738B (zh) * 2018-08-29 2020-10-16 浙江工业大学 一种依鲁替尼的溶剂化物及其制备方法
JP7417356B2 (ja) 2019-01-25 2024-01-18 株式会社ソニー・インタラクティブエンタテインメント ロボット制御システム
US11285159B2 (en) 2019-11-05 2022-03-29 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540577A (ja) * 2005-05-12 2008-11-20 アボット・ラボラトリーズ アポトーシス促進剤
WO2009155386A1 (en) * 2008-06-20 2009-12-23 Abbott Laboratories A process for the preparation of the apoptosis promoter abt-263

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2713507A (en) 1948-10-04 1955-07-19 Garlinghouse Brothers Concrete bucket
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7075365B1 (en) 2004-04-22 2006-07-11 Altera Corporation Configurable clock network for programmable logic device
EP2061560A2 (en) * 2006-09-05 2009-05-27 Abbott Laboratories Bcl inhibitors for treating platelet excess
JP4202380B2 (ja) * 2006-10-17 2008-12-24 シャープ株式会社 画像形成装置
MX2010006260A (es) 2007-12-06 2010-08-23 Abbott Lab Composiciones orales de abt-263 para tratar cancer.
CN101220008B (zh) * 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8140876B2 (en) * 2009-01-16 2012-03-20 International Business Machines Corporation Reducing power consumption of components based on criticality of running tasks independent of scheduling priority in multitask computer
JP2010259520A (ja) 2009-04-30 2010-11-18 Motoji Ono 搬送機構、トレッドミル及びコンベア
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20110047552A1 (en) * 2009-05-11 2011-02-24 Raytheon Bbn Technologies Corp. Energy-aware process environment scheduler
US8291422B2 (en) * 2009-05-11 2012-10-16 Bbn Technologies Corp. Energy-aware computing environment scheduler
CN105820138A (zh) 2009-09-20 2016-08-03 Abbvie 公司 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物
CN101798292A (zh) * 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540577A (ja) * 2005-05-12 2008-11-20 アボット・ラボラトリーズ アポトーシス促進剤
WO2009155386A1 (en) * 2008-06-20 2009-12-23 Abbott Laboratories A process for the preparation of the apoptosis promoter abt-263

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDER R: "DISCOVERY OF AN ORALLY BIOAVAILABLE SMALL MOLECULE INHIBITOR OF PROSURVIVAL 以下備考", JOURNAL OF MEDICINAL CHEMISTRY, vol. V51 N21, JPN5012016697, 8 October 2008 (2008-10-08), pages 6902 - 6915, ISSN: 0002904203 *
WANG G: "AN EFFICIENT SYNTHESIS OF ABT-263, A NOVEL INHIBITOR OF ANTIAPOPTOTIC BC1-2 PROTEINS", SYNTHESIS, vol. V15, JPN5012016696, 1 January 2008 (2008-01-01), DE, pages 2398 - 2404, ISSN: 0002904202 *
有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0002904204 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014162794A (ja) * 2013-02-21 2014-09-08 Pfizer Inc 選択的ｃｄｋ４／６阻害剤の固体形態
JP2017186376A (ja) * 2013-02-21 2017-10-12 ファイザー・インク 選択的ｃｄｋ４／６阻害剤の固体形態

Also Published As

Publication number Publication date
RU2012115851A (ru) 2013-10-27
IL218403A0 (en) 2012-04-30
CA2771984A1 (en) 2011-03-24
AU2010295717B2 (en) 2014-09-11
US8362014B2 (en) 2013-01-29
TWI488853B (zh) 2015-06-21
ZA201202891B (en) 2013-09-25
CN102695702A (zh) 2012-09-26
JP2015232006A (ja) 2015-12-24
AU2010295717A1 (en) 2012-03-22
NZ598461A (en) 2013-12-20
BR112012006252A2 (pt) 2017-05-23
TW201116526A (en) 2011-05-16
US20110071151A1 (en) 2011-03-24
KR20120085781A (ko) 2012-08-01
US20110294811A1 (en) 2011-12-01
EP2477972A1 (en) 2012-07-25
MX2012003408A (es) 2012-08-03
WO2011034934A1 (en) 2011-03-24
US8513243B2 (en) 2013-08-20
CN105820138A (zh) 2016-08-03
RU2551376C2 (ru) 2015-05-20

Similar Documents

Publication Publication Date Title
US8362014B2 (en) ABT-263 crystalline forms
US8362013B2 (en) Salt of ABT-263 and solid-state forms thereof
US8728516B2 (en) Stabilized lipid formulation of apoptosis promoter
JP5779591B2 (ja) Ａｂｔ−２６３カプセル剤

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150717

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150810

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20151023